MOG-modified autologous CD4+ T cells

**MOG-modified autologous CD4+ T cells** are a form of cell therapy in which a patient's own CD4+ T cells are genetically modified to recognize the myelin oligodendrocyte glycoprotein (MOG) antigen. MOG is associated with autoimmune demyelinating diseases such as MOG antibody-associated disease (MOGAD). These cell therapies are designed to alter the immune response by specifically targeting MOG, aiming to either modulate or suppress autoreactive T cell responses implicated in disease pathology. Although multiple types of MOG-specific T cell therapies have been described in experimental and early clinical contexts, current clinical evidence for MOG-target-modified T cell therapies is extremely limited. No fully characterized, named, or commercialized product with this exact specification appears to be in late-stage clinical use or approved as of September 2025.